Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering
September 16, 2022 08:42 ET
|
Benitec Biopharma Inc.
HAYWARD, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing...
Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering
September 12, 2022 22:06 ET
|
Benitec Biopharma Inc.
HAYWARD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing...
Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update
September 02, 2022 08:00 ET
|
Benitec Biopharma Inc.
HAYWARD, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing...